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ABSTRACT 
The purpose of this project was to investigate the role of melatonin in the 
pathophysiology of anxiety in humans. 
The literature study confirmed the intimate relationship between 
serotonin and melatonin. Melatonin is not only able to act as an agonist 
(in physiological concentrations) and an antagonist (at higher 
concentrations) on serotonin receptors but via control of brain pyridoxal 
kinase activity might have an effect on GABA, serotonin, dopamine and 
norepinephrine synthesis. 
A clinical trial to investigate melatonin's effect on anxiety in humans was 
conducted as a pilot study. Thirty patients complaining of anxiety 
participated in a liN of 1" double blind placebo controlled trial. During the 
experiment each subject was thus exposed to melatonin and a placebo 
for a week at a time on two occasions. 
During the first phase of the experiment, (Pair '1) patients showed a 
statistically significant reduction in their anxiety levels during the first 
period (P1P1), which was not the case during the second period (P1P2). 
The improvement however continued during the second phase of the 
experiment (Pair 2) so that there was also a statistically significant 
improvement during P 2 P 2 (Period 2 / Pair 2) when placebo was 
administered. 
II 
It could not conclusively be shown that melatonin was responsible for the 
improvement in the patients' anxiety. 
The explanation for these results suggests thelt the improvement was 
due to a: 
1) placebo effect throughout, 
2) psychotherapeutic effect due to contact with a clinician, 
3) melatonin induced phase shift in the patient's endogenous 
melatonin response curve, 
4) combination of all 3 options. 
This pilot study lays the groundwork for a much more exhaustive study in 
which the melatonin of the patients is determined before melatonin is 
administered, the role of the clinician is clarified and the most 
appropriate time for melatonin administration is sought. 
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CHAPTER 1: INTRODUCTION 
Interest in the pineal gland began in 300 BC when it was discovered by 
Herophilus. Over the centuries, as scientific methods developed, the in 
depth study and accumulation of knowledge regarding the pineal gland 
intensified.(1 ) 
Besides the fact that the pineal gland is instrumental in regulating the 
day/night cycle it is also implicated in a variety of psychiatric 
disorders.{1 )(2) It is important to realise that there is not a simple 
relationship between the pineal gland (melatonin) and any of these 
disorders, but that it probably forms part of a complex dysfunctional 
process - there are thus good reasons why the pineal gland is called "the 
regulator of all regulators."(2) 
The anxiolytic properties of melatonin are poorly documented - it has 
been demonstrated in mice that melatonin exhibits anxiolytic 
properties.(3) 
Because melatonin is safe to administer to humans (4) and appreciating 
the suffering endured by humans due to anxiety, the anxiolytic effect of 
oral melatonin in humans is to be investigated. 
An interesting extension of this study would be to investigate by means 
of a literature survey the possible interaction of melatonin with serotonin 
receptors and other neurotransmitter systems. The rationale of this is 
the comorbidity between anxiety and depression and the possibility that 
both may be due to dysfunctional 5HT1A autoreceptors.(5) 
2 
This project is seen as a pilot study on the anxiolytic properties of 
melatonin. This study should add another dimension to the further 
clinical investigations into the pathophysiology of anxiety - that of 
melatonin phase response abnormalities. 
The interactions of melatonin with other systems are presented in a flow 
diagram. The content and purity of "over the counter" melatonin in 
human research is also addressed by the analysis of melatonin tablets. 
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CHAPTER 2: THE HUMAN PINEAL GLAND 
2.1 INTRODUCTION 
The pineal gland was once described by Descrates as the seat of 
the soul. The human pineal gland is anatomically close to the 
third ventricle and the anatomical relationships are similar to those 
of the lower mammals.(1) 
2.2 EMBRYOLOGY 
The nervous system is ectodermal in origin and develops from the 
neural plate. From a hollow tubelike structure the central nervous 
system develops so that its caudal (tail) portion forms the spinal 
cord and the cephalic region the brain. 
The brain is subdivided into 3 parts: 
a) The prosencephalon (forebrain) which consists of: 
• The telencephalon (rostral) 
• The diencephalon (caudal) 
b) The mesencephalon 
c) The rhombencephalon which consists of: 
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• The metencephalon (pons & cerebellum) 
• The myelencephalon (medulla). 
See fig 1 (a) and fig 1 (b) (6) 
The pineal gland develops from the diencephalon (caudal part of 
the roof plate) which also gives rise to the thalami, geniculate body, 
most of the hypothalamus, the roof of the third ventricle and the 
neurohypophysis. (7) 
2.3 ANATOMY 
The pineal gland is attached to the posterior roof of the third 
ventricle and lies between the posterior commissure and dorsal 
habenular commissure.(6)(7)(8) The human pineal is about 5 by 7 
millimeter in size and weighs 100-150 milligram. It is covered by 
the pia mater which forms a capsule and sends septa inwards to 
form lobules.(8) 
2.4 BLOOD SUPPLY 
The posterior cerebral arteries, which are the two terminal 
branches of the basilar artery, branch into the posterior choroidal 
arteries(3); the medial posterior choroidal branches supply the 
pineal gland.(8)((9) See fig 2.(10)). The bloodflow is in the region 
of 4 millilitre/minute/gram, second only to the kidney. Arteries 
branch extensively in the capsule before entering the parenchyma. 
The extensive vascular bed contains vessels the size of capillaries. 
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It seems that the cortical pineal tissue receives 1.2-2.0 times the 
blood flow of the medullary pineal. The blood supply of the pineal 
is also higher during the night. Removal of the superior cervical 
ganglia reduces the metabolic activity of, and the blood flow to, the 
pineal gland.(9) The pineal gland's capillaries are fenestrated with 
a high degree of permeability. It is thus one of the 
circumventricular organs (outside the blood brain barrier).(11) 
2.5 VENOUS DRAINAGE 
The pineal capillaries network empties in the great cerebral vein. 
In humans there is also drainage into the junction of the internal 
cerebral veins.(9) There appears to be a vascular resistance of 
intrinsic pineal vessels to venoreflux or backflow.(12) 
2.6 NERVOUS SUPPLY 
The nervous control of the pineal gland involves post-ganglionic 
sympathetic fibres from the superior cervical ganglion as we" as 
input from the parasympathetic, commissural and peptidergic 
systems. The post-ganglionic fibres take their course via the 
internal carotid plexus (blood vessels) and form the nervi conarii 
before entering the gland. The nerve terminals do not form 
synapses with pinealocytes - they end in the vicinity of pinealocyte 
processes, around capillaries in many cases.(9) 
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The sympathetic innervation controls the production of melatonin-
the major neurotransmitter being noradrenalin. The pineal gland is 
connected to the retina via the superior cervical ganglia (SCG) and 
the hypothalamic suprachiasmatic nuclei.(13) See fig 3.(9) 
2.7 HISTOLOGY 
The lobules of the pineal gland consist of pinealocytes and 
neuroglia. The pinealocytes which are best seen in silver 
preparations are irregular cells with long branching processes 
terminating in bulbous endings. The cytoplasm is noted for its 
extensive smooth endoplasmic reticulum. Brain sand (acervuli) is 
mainly in the capsule and septa.(14) 
Calcification in the pineal gland was once regarded as a sign of 
degeneration. It has however been shown that the amount of 
calcification is not proportional to the age of the patient.(15) 
2.8 PINEAL CONTENT 
The pineal gland not only contains indoleamines but also 
polypeptides (example arginine vasotonin). (16)(17) Other indoles 
related to melatonin exist in the pineal. 5-Methoxytryptamine for 
example is an agonist on 5HT1A receptors and may be involved in 
the modulation of serotonergic transmission.(18) 
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CHAPTER 3: MELATONIN 
3.1 HISTORY 
Melatonin was discovered by Lerner and his colleague in 
1958.(18) This followed the interest in 5- Hydroxytryptamine 
during the 1950's which led to the development of the concept 
of a system that was able to synthesize biogenic amines -
"Amine precursor uptake and decarboxylation system (APUD)." 
Interestingly there is an inverse relationship of serotonin and 
melatonin concentrations in the pineal gland - serotonin levels 
being highest during the daytime.(19) 
3.2 SYNTHESIS 
Fig 4 Melatonin: synthetic pathway.(1 )(19) 
Melatonin is synthesized and secreted by the pineal gland 
during the dark phase of the day and is under noradrenergic 
control (post ganglionic sympathetic fibres.)(20) 
The pineal gland takes up tryptophan from the circulation which 
is then hydroxylated and decarboxylated to serotonin. 
N - acetyltransferase (NAT) (with 70-100 fold increased activity 
at night) is in most circumstances the rate limiting enzyme in 
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melatonin synthesis. The final step is the transfer of a methyl 
group to N-acetylserotonin by the enzyme Hydroxyindole - 0 -
methyltransferase (H 10M T).(21) It has been hypothesized 
that decreased melatonin biosynthesis might have been due to 
the impairment of calcuim dependent steps (for example 
binding of calcium to N - acetyltransferase activates the 
enzyme) in the melatonin pathway.(22) 
3.3 METABOLISM I PHARMACOKINETICS 
Melatonin undergoes metabolism primarily within the liver and 
secondarily in the kidney. It follows a microsomal phase 1 I 
phase 2 reaction - hydroxylation followed by sulfate or 
glucoronide conjugation. Exogenous melatonin is demethylated 
to N-acetylserotonin which is then metabolized like melatonin. 
Exogenous (oral or intravenous) melatonin undergoes a large 
hepatic first pass effect and has a short metabolic 
half-life.(19)(23) 
Oral melatonin shows a peak level after 60 minutes. Plasma 
concentrations remain elevated for between 3- 7 hours (oral 
dose 2-Smg). 
Oral melatonin has a low bioavailability (0,03- 0,76).(24) 
See Table1, 2 and Fig 6 for pharmacokinetic data of melatonin 
after bolus intravenous (I.V.) injection, infusion over S hours and 
oral intake. The difference between the values of Iguchi and 
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those reported by Mallo et al (Table 1) are thought to reflect a 
difference between Asian and European people in their ability to 
metabolize melatonin.(23)(25) 
3.4 CIRCADIAN RHYTHMS AND MELATONIN 
Circadian rhythms are biological rhythms that are + 24 hours 
long. (e.g. hypothalamus - hypophysis controlled cycles) 
Other biological rhythms are: 
* infradian (longer than 24 hours) e.g. menses, hibernation, 
fertility) 
* ultradian (shorter than 24 hours) 
* diurnal/nocturnal - events during day/night.(26) 
Biological rhythms are frequently determined by a combination 
of external and internal factors. In the absence of any time 
cues, the endogenous period (tau(t)) of a rhythm is said to be 
free-running. (for example t in humans is 22-26 hrs) 
External factors which synchronize a rhythm are known as 
zeitgebers. 
The suprachiasmatic nucleus serves as the pacemaker for 
endogenous rhythms.(27) 
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TABLE 1 Individual and mean pharmacokinetic parameters 
after intravenous bolus injection of melatonin (25) 
Subjects CM LM MD RZ Mean Value (SD) Iguchi' 
(weight, kg) 66 68 60 63 64.2 (3.5) et al. 
disappearance rate constant a (min -I) 0.480 0.359 0.608 0.305 0.438 (0.116) 0.224 
r 0.978 0.997 0.941 0.984 
half-life tllZ a (min, s) 1.26 1.56 1.08 2.12 1.35 3.05 
disappearance rate constant ~ (min -I) 0.0232 0.0221 0.0228 0.0286 0.024 (0.002) 0.15 
r 0.88 0.976 0.95 0.98 
half-life t'l2 ~ (min, s) 29.51 31.31 30.18 24.15 28.40 46.15 
volume of central compartment (Vc.l) 11.2 19.8 11.2 10 13.0 (4.5) 13 
apparent volume of distribution 
at steady-state V .. (I) 35.7 39.7 36.2 29 35.1 (4.4) 35.2 
• elimination rate constant k., (min -I) 0.0854 0.0433 0.0815 0.1181 0.0821 (0.0306) 0.0453 
area under curve AVC (~g. min·ml- I) 5.2 x 10-) 5.8 X 10-3 5.2xlO- J 9.2 X 10- 3 15.8 X 10-3 
systemic clearance CL. (mi· min -I) 958 856 963 1087 966 (94.5) 630 
, recalculated from the data of Iguchi et al. 1982 
• elimination constant rate. k.h was calculated from the hybrid rate constants B, and B2 and the rate constant kll for transfer between compart-
ments 2 and 1: k., = B,Bik21 . 
eM, LM, MD received 51-19 I.V. bolus. 
RZ received 101-19 I.V. bolus. 
r: goodness of fit parameter 
TABLE 2 Individual and mean pharmacokinetic parameters 
from the falling part of the plasma melatonin profile 
in healthy controls after the end of the infusion . (25) 
Subjects BPH CM MD MP RJF RZ mean (SD) 
(weight, kg) 87 66 60 66 84 63 71 (11.5) 
disappearance rate constant a (min -') 0.256 0.101 0.185 0.558 0.472 0.144 0.286' (0.170) 
half-life tin a (min, s) 2.42 6.51 3.44 1.14 1.28 4.48 3.27 (1.57) 
disappearance rate constant ~ (min -I) 0.0126 0.0149 0.0238 0.0102 0.0184 0.0166 0.0160· (0.0043) 
half-life tliZ ~ (min, s) 55 46.30 29.07 67.56 37.39 41.44 45.39 (12.48) 
elimination rate constant k., (min -I) 0.0231 0.0164 0.0299 0.0182 0.0271 0.0272 0.0236 c (0.0054) 
mean plasma melatonin concentration 
at the plateau (pg. ml- ') 100 84 . 76 58 53 62 72.1 (17.8) 
V.(I) =(1+ ~\-2)V\ 50.9 52.9 35.7 111.0 67.1 60.6 63.0 
2-\ 
. 
• no significant difference when compared to a given in Table 1 
• a significant difference (P < 0.02) was observed using the t-test when compared to ~ given in Table 1 
., 
C a significant difference (P < 0.001) was observed using the t-test when compared to k.,given in Table 1 
Subjects received Melatonin (0.4 11m I ml) as a constant infusion of 10 ml per hour for three hours starting at l1hOO 
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Zeitgebers (time, light/dark, social cues) with a period T, change 
endogenous periods to run along their own period T. 
Depending on whether t is less than 24 hours, or t is more than 
24 hours, there will be a phase delay/advance in the 
pacemaker. (28). 
Melatonin is secreted during the night. Peak concentration 
occurs between 02-04 hrs. In absence of light, human 
melatonin rhythm is free-running with t greater than 24 hours. 
Optimal sampling times for assessment of melatonin peaks on 
consecutive days appears to between 23hrs-01 hrs.(29) 
The stability of normal melatonin rhythm in individual humans 
(resistance to nutritional/metabolic change) causes small 
changes in the phase of melatonin secretion to be of clinical 
significance. During winter there is a melatonin phase delay of 
approximately 1-2 hrs.(30) 
3.5 ASSOCIATION WITH PSYCHIATRIC DISORDERS 
3.5.1 Anxiety 
Anxiety is a normal emotion as a response to a threat or stress. 
If an individual's performance (behaviour) however deteriorates 
as a result of anxiety, this can be regarded as a pathological 
condition. (See fig 7(a): Yerkes Dodson Law).(31) 
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Functional psychiatric Medically induced Substance induced 
condiction anxiety anxiety 
1) Anxiety disorders 1) Cardiovascular 1) Intoxication 
• Panic disorder • Anaemia • Cocaine 
• Social Phobia • Angina • Theophyllin 
• Obsessive compulsive • Heart failure • Nicotine 
disorder • Mitral valve prolapse • Caffeine 
• Acute and Post traumatic 
stress disorder 
• Generalized anxiety 
disorder 
2) Depression 2) Pulmonary 2) Withdrawal 
• Asthma • Alcohol 
• Hyperventilation • Opiates 
• Benzodiazepines etc. 
3) Psychotic disorders 3) Neurological 
• Stroke 
• Epilepsy 
• Migraine etc. 
4) Personality disorders etc. 
Table 3 Causes of anxiety - examples 
Performance 
(= behaviour) 
19 
Normal anxiety 
Intermediate 
platea u phase 
.. 
Drive (= Anxiety) 
Fig 7(a) Yerkes - Dodson Law 
Pathological 
anxiety 
• 
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Anxiety can be regarded as a symptom (what patient complains 
of), a clinical sign (as observed by clinician, e.g. facial 
expression, a tremor) or a syndrome (i.e. one of the anxiety 
disorders). 
Before the diagnosis of a functional anxiety disorder can be 
made the patient needs to be carefully evaluated for medical 
causes (mitral valve prolapse, epilepsy, Cushings etc.), 
substance induced anxiety (cocaine, marijuana, caffeine, 
theophyllin) or other psychiatric disorders in which anxiety can 
be prominent (depression, personality disorder, schizophrenia 
etc). See table 3. 
More than one neurotransmitter is implicated in anxiety -
gamma - aminobutyric acid (GABA), noradrenaline and 
serotonin may all be involved as suggested by the therapeutic 
response to tricyclic antidepressants, bensodiazepines, 
selective serotonin re-uptake inhibitors and the azapirones. A 
detailed discussion of these mechanisums is not attempted for 
the purpose of this study. 
It is well known that the benzodiazepines act as a GABA -
neuromodulators (increases GABA binding) - GABA being an 
inhibitory neurotransmitter. 
Other ligands of the benzodiazepine receptor - inverse agonists 
- are anxlogenlc. 
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The benzodiazepine antagonist flumazenil provokes panic 
when given intravenously to patients suffering from a panic 
disorder.(32) 
From clinical experience we know that the tricyclic anti-
depressant imipramine (a noradrenaline re-uptake inhibitor 
amongst many other things) is effective in panic disorder. 
Drugs affecting the serotonergic system (for example the 
selective serotonin re-uptake inhibitors and the azapirones) are 
currently used for long term treatment of anxiety disorders and 
evidence is mounting that the azapirones also have 
antidepressant properties.(33)(34)(35) 
The use of melatonin in rats has been shown to promote sleep, 
cause sedation and analgesia and has anticonvulsant activity. 
Indications are that the anxiolytic properties of melatonin in rats 
may be modulated through the GABA-ergic system. Flumazenil 
also blunts melatonin's effect.(3)(36)(37) 
Melatonin treatment increases GABA - turnover in the 
hypothalamus and the pineal gland.(38) Melatonin was also 
shown to enhance GABA - binding in rat brain. There are also 
indications that the central (central nervous system) effect of 
melatonin may involve the adrenergic and serotonergic 
systems.(39) 
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Amaroli (early morning auto-urine drinking) is believed to 
promote meditation by restoring plasma melatonin levels to that 
of night-time levels.(28) 
Melatonin was shown to playa role in the regulation of the 
serotonergic system. The effectiveness of 5-HT reuptake 
inhibitors in the treatment of obsessive compulsive disorder 
(OeD) may be related to this relationship. Fluvoxamine 
administration significantly increases melatonin levels after 
24 hours, while tranylcypramine, pirlindole (a mono amine 
oxidaze type A inhibitor) and mianserin had no such 
effect. (40)(41 ) 
Naloxone, which exacerbates OCD, also antagonises the 
analgesic and sedative effects of melatonin.(40) 
There are indications from clinical work that patients with panic 
disorder may have a phase delay of their melatonin circadian 
rhythms. The fact that alprazolam and light therapy suppress 
nocturnal melatonin secretion suggests that seasonal affective 
disorder (SAD) and panic disorder, which are both seasonal, 
may be related by both causing phase instability of the circadian 
rhythm.(42) 
It has been shown that the effect of stress on gastric ulceration 
in rats could be countered by the administration of exogenous 
melatonin.(43) 
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3.5.2 Depression 
Seasonal affective disorder which occurs in autumn or winter is 
characterized by depression, psychomotor slowing, 
hypersomnia and hyperphagia. Patients respond to bright light 
exposure (2500 Lux) of 2 hours per day - either in the morning 
(gives melatonin phase response advance) or in the evening 
(gives melatonin phase response delay).(44) 
It was noted in clinical research that 2 hours bright light 
exposure was more effective than 30 minutes exposure.(45) 
Investigation also showed that patients with major depression 
and an abnormal dexamethasone suppression test (DST) had a 
significantly higher cortisol/melatonin (c/m) ratio than did 
patients with a normal DST. Low melatonin in these patients 
may indicate pineal gland dysfunction.(46) 
Manic-depressive patients' exposed to light of 500 Lux 
(between 02hOO - 04hOO) had a 50 per cent suppression of 
melatonin levels, but similar exposure had no effect on control 
patients' nocturnal melatonin secretion.(47) 
Because acute tryptophan depletion can decrease melatonin 
secretion significantly, it was suggested that abnormal 
serotonergic function (tryptophan is the precursor of serotonin) 
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in some depressed patients, might be reflected as decreased 
melatonin levels in these patients, as serotonin is an 
intermediary in the production of melatonin.(48) 
There are, however, no consistent findings to confirm the low 
melatonin - hypothesis in depression(49)(50) and there is 
evidence that nocturnal melatonin secretion is not reduced in 
depression.(51 ) 
Currently positron emission tomography (PET) is utilised to 
investigate metabolic patterns in the brain caused by light 
therapy.(52) 
Studies using 24-hour urinary output of 6-sulphatoxy -
melatonin as an index of pineal activity (instead of periodic 
plasma/serum melatonin estimations) indicated a significantly 
higher output of 6-sulphatoxymelatonin when patients were on 
treatment with desipramine (a noradrenegic antidepressant). 
The fact that melatonin secretion from the pineal gland is under 
noradrenegic control suggests that 6-sulphatoxymelatonin 
reflects increased l1-adrenergic activity in the pineal gland and it 
could thus be useful to evaluate down regulation of l1-receptors 
in patients receiving antidepressant treatment. (53) 
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3.5.3 Sleep 
Sleep can be regarded as an active process which can be 
characterized by means of electroencophalogram, electro-
oculogram and electromyogram recordings. (54) 
This complex physiological state has been shown to consist of 
alternating patterns of rapid eye movement (REM) sleep and 
non rapid eye movement sleep.(NREM) 
See fig.7(b) 
The sedative effect of melatonin reported in earlier studies, 
which were thought to be a side-effect, is now regarded as part 
of the physiological role of melatonin. This is thought to occur 
through the regulation of the circadian rhythm rather than the 
hypnotic effect of melatonin as such.(55) 
Light is a zeitgeber affecting circadian rhythm - in totally blind 
people up to 50 per cent have free running circadian rhythms 
greater than 24 hours.(55) This is associated with sleep 
disturbances. 
Clinical studies suggested that exogenous melatonin may 
modulate the circadian rhythm in blind and non-blind people. 
(56)(57) 
On the other hand normal melatonin secretion in a patient with 
Kleine-Levin Syndrome (Periodic somnolence and morbid 
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hunger) suggests that melatonin secretion is not directly linked 
to sleep.(58) 
The influence of melatonin on the suprachiasmatic nucleus, 
which has been found to be a major sleep regulator, has 
recently come to Iight.(59) 
The abundance of REM sleep during the first three months of 
infancy is associated with low melatonin levels - this has given 
rise to the theory that increased melatonin levels decrease REM 
sleep.(60) 
It was shown that exposure to bright light increases REM-sleep 
latency and the duration of NREM sleep. Delayed REM sleep 
after bright light exposure is speculated to represent a 
circadian phase shift.(61) 
Melatonin's sedative hypnotic effect (62) was confirmed in 
rodents and it was speculated that interaction with brain 
benzodiazepine receptors was a possibility (63) - it was for 
instance shown that flumazenil (a benzodiazepine antagonist) 
blocks the effect of melatonin on GABA binding in the rat 
cerebellum.(37) 
Chronic insomniacs may benefit from oral intake of melatonin. 
A two to three day delay in response was shown.(64) The time 
of melatonin administration may also be important when 
28 
treating sleep disturbances - there may be a "dead zone" of the 
phase response curve.(S5) 
3.S ASSOCIATION WITH OTHER DISORDERS 
3.6.1 Cancer 
Reports that cancer patients' pineal glands are larger than 
non-cancer patients, have led to the idea that the pineal gland 
may playa role in inhibiting tumor growth - possibly by inhibiting 
endocrine systems that stimulate tumor growth.(66) 
3.S.2 Puberty 
Plasma melatonin declines during development. Administration 
of melatonin to male and female rats delays puberty. It was 
shown that after induction of secondary sexual charactaristics in 
a patient with infantilism due to a craniopharyngioma that there 
was a decline in U-S-sulphatoxymelatonin (index of melatonin 
production). Hypothalamic amenorrhoea is also accompanied 
by high melatonin levels.(S7) 
There is a report of a patient with delayed puberty and 
hypogonadotrophic hypogonadism where his high plasma 
melatonin level (and a enlarged calcified pineal of 18mm) was 
suspected to be the cause of his hypogonadism. Why the 
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patient's melatonin secretion normalised over a seven-year 
period is unknown but this was accompanied by complete 
maturation of his pituitary-gonadal function.(68) 
Growth hormone (GH) secretion is stimulated by growth 
hormone releasing factor (GRF) and inhibited by somatostatin. 
It has been established that the pineal gland plays a role in 
regulation of growth and GH secretion in rodents. Oral 
administration of melatonin causes a small increase in basal 
GH-Ievels in normal human subjects and GH respons to GRF. 
However, melatonin reduces GH response to insulin - induced 
hypoglycaemia. It was proposed that the latter stimulates GH 
release from the hypothalamus.(69) 
It is important to remember that although nocturnal melatonin 
levels progressively drop by 80 per cent from childhood until 
adult levels are reached, this appears to be due to an increased 
volume of distribution (Vd) of melatonin during development. 
Melatonin production is constant during childhood.(49) 
Nighttime melatonin plasma levels are approximately: 
* 250pg/ml at age 1-3 years 
* 120pg/ml at age 8-15 years 
* 20pg/ml at age 50-70 years 
Daytime melatonin plasma levels are + 4-1 Opg/ml regardless of 
age. 
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3.6.3 Ageing 
Speculation is that melatonin may exhibit anti-ageing 
properties. (66) It has even been suggested that ageing is a 
pineal failure and that a decrease in melatonin/serotonin ratio 
leads to arteriosclerosis and increased cell membrane 
thickness. This can lead to diminished diffussion of nutrients 
into and waste products out of cells.(70) 
3.6.4 Circadian Rhythm disorder 
Melatonin may playa role in development (example onset of 
puberty) and ageing (lifespan). It also is important in circadian 
rhythm (locomotor activity, body temperature) and in seasonal 
cycles {example reproduction).(71 )(72){73) 
Evidence points to the SCN (of the hypothalamus) as the site 
that generates circadian rhythms in mammals.(27) 
Nightwork causes a disruption in circadian rhythm that not only 
leads to sleep disturbances but also to an increased risk of 
other disorders. (Gastrointestinal, cardiovascular).{74) 
Exposure to bright light (7000 - 12000 Lux) at night and 
complete darkness during the day contribute to circadian 
adaptation to daytime sleep / nighttime work. 
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It has been proposed that changes in circadian rhythms are 
indicative of ageing and accompanying cognitive decline.(75) 
Bright light was shown to be able to reset the human circadian 
pacemaker - which can be important in the treatment of delayed 
sleep phase insommia, jet lag and shift work insommia. 
(76)(77){78) 
It has been shown that a 60 per cent reduction in eastward jet 
lag and 40 per cent reduction in westward jet lag is possible by 
taking 5mg melatonin, according to instructions (to induce a 
phase advance when travelling eastward and a phase delay 
when travelling westward).{79) See fig 8. It seems that 
eastward flights are associated with bigger acclimatisation 
problems.(80) 
3.6.5 Pineal Tumor 
Patients with pineal tumors are rare. It appears that estimation 
of melatonin plasma levels is a reliable way to assess the 
success of pinealectomy.(81) It is reported that low day time 
levels of melatonin are unaffected after pinealectomy. The 
dynamics of the decline of melatonin level after pinealectomy 
have not been investigated.(81) 
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3.6.6 Immune system 
Melatonin seems to stimulate the immune response in some 
conditions - the opiatergic system possibly plays a role. No 
melatonin specific receptors have so far been found on cells of 
the immune system.(49) It was noted that the thymus might be 
one of the main targets of melatonin (81) and that melatonin is 
involved in the production of Interleukin-2(70). 
3.6.7 Other 
Patients with primary hypothyroidism were shown to secrete 
more melatonin during the night when compared to normal 
patients. Thyrotoxic and obese patients secreted normal 
amounts of melatonin but thyrotoxic patients showed a phase 
advance.(82) 
3.7 MELATONIN AND SEROTONIN 
3.7.1 Introduction 
Serotonin is transformed to melatonin in the pineal gland. Due 
to this "relationship" there seems to be a very special protection 
mechanism to maintain a stable serotonin status in the pineal 
gland. Although the concentration of serotonin in the pineal 
gland is hundred-fold that of the brain concentration, the brain 
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serotonin levels in experimental animals drop before any 
decrease in pineal serotonin levels occurs.(83) 
The interaction of melatonin with brain serotonin (and possibly 
other brain monoamines as well) which leads to catecholamine 
synthesis may be mediated through melatonin's effect on brain 
pyridoxal kinase activity - the latter being essential for the 
synthesis of brain gamma aminobutyric acid, serotonin, 
dopamine and norepinephrine. Both melatonin and pyridoxal 
kinase activity peak at midnight. 
There is evidence that melatonin acts as an inhibitor on the 
pituitary-adrenal axis by activating the central adrenergic 
system that is responsible for controlling the secretion of 
adrenocorticotrophic hormone (ACTH). 
A rise in brain catecholamines after the administration of 
melatonin may lead to a reduction in the stress response in 
animals. 
It is suggested that central catecholamines and 5-HT are 
capable of working together at least as far as melatonin -
induced behavioural modulation - (which is inhibitory in nature) 
is concerned. 
The interactions between melatonin and other neuropeptides on 
behaviour cannot be ignored.(84) 
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3.7.2 Serotonin 
3.7.2.1 General 
Serotonin was first isolated from blood serum and called 
enteramine. It was recognised to be a vasoconstrictor and 
that blood platelets could concentrate serotonin. 
In the central nervous system (eNS) the brainstem contains 
most of the sumtotal of serotonin (although the pineal 
serotonin concentration is the highest). 
Serotonin crosses the blood-brain carrier with difficulty. It 
was once postulated that melatonin may be a lipid soluble 
derivative of serotonin, thereby enabling it to gain easy 
entry into nerve cells and then to be converted back to 
serotonin which is then the active substance.(85) 
Serotonin can function as a neurotransmitter, and 
serotonergic transmission is important in anxiety and sleep. 
Benzodiazepines can depress serotonergic metabolism in 
the brain of the mouse - it was proposed that the availability 
of tryptophan as a precursor was changed by the 
benzodiazepines. (86) 
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When argentaffin cells become cancerous (carcinoid), over-
production of serotonin results. These patients present with 
vasodilatation (flushing of skin) and severe diarrhoea. 
Some patients have high blood pressure.(85) 
3.7.2.2 Serotonin receptors 
Different 5-HT-receptors seem to be linked to different 
second messenger systems and as well as to ligand-gated 
ion channels. 
Up to date 7 classes of serotonin receptors have been 
described (5-HT1 - 5-HT7)' Most of these classes consist of 
more than one member. 
With the exception of the 5-HT 3 - receptors, which are 
ligand-gated ion channel receptors, the 5-HT receptors 
interact with G-proteins. Based on their interaction with 
second messengers and their amino acid sequence 
homology the latter were seperated into distinct families 
e.g.: 
(i) 5 HT1 family - Negatively coupled to adenylate cyclase 
(ii) 5 HT2 family - activation of phospholipase C. 
(iii) A heterogenous group (5-HT4' 5HT6 , 5HT7) - positively 
coupled to adenylate cyclase.(87)(88) 
37 
The Serotonin Receptor Nomenclature Committee of the 
International Union of Pharmacology (NC-IUPHAR) however 
reclassified the 5-HT receptors in 1994 and recognised the 
following: 
* 5-HT1 (5-HT1A. 5-HT1B. 5-HT1D• 5-ht1B' 5-ht1E and 
5-HT1-like) 
* 5-HT 3 
* 5-HT 4 
* Recombinant (5-htsA' 5-HTsB. 5-h~ and 5-ht7) 
* 'Orphan' receptors 
It is now suggested that the terminology '5-HT1 - like 
receptors' is outdated. because it does not take into account 
the sumatriptan-insensitive (5-HT1Y) receptor which is 
positively coupled to adenylate cyclase (prodilator receptor). 
Investigations of the 5-HT1-like receptors thus yielded 3 
distinct receptors namely sumatriptan-sensitive (5-HT1B. 
5-HT1D) and sumatriptan-insensitive (5-HT7).(89) 
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3.7.2.3 Clinical implications: Serotonin Receptors and their relation 
to behaviour 
Speculation on the role of serotonin in psychiatric disorders, 
especially depression, is not new.(90) 
It was shown that the serotonergic agonist (91) metachloro-
phenylpiperazine (mCPP) exacerbates obsessive-
compulsive symptoms in patients with obsessive-compulsive 
disorder. Furthermore the SSRl's are useful in the treatment 
of OCD. This points to a serotonergic role in the pathology 
of OCD.(92) 
There is evidence that serotonergic neurotransmission is 
decreased in the presence of benzodiazepines. The 5-HT1A 
receptor is also implicated as presynaptic 5-HT1A- partial 
agonists e.g. buspirone, are effective anxiolytics(93) -
especially for the treatment of generalized anxiety disorder. 
Activation of post-synaptic 5-HT1A receptor in rats produces 
the 5-HT-behavioral syndrome (fore-paw treading, hind limb 
abduction, low body posture, tremor, head weaving and 
straub tail). 
Antidepressants were also shown to cause a diminished 
5-HT2 receptor density in the frontal cortex of rats. This was 
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accompanied by a reduction in the magnitude of behavioural 
responses elicited by 5-HT2 - agonists.(94) 
Studies of abnormal motor behaviours induced by chemical 
manipulation in rats implicate 5-HT receptors in a myoclonic-
serotonergic syndrome.(95) Serotonin - like behaviour 
induced by high doses of clonidine however does not seem 
to be related to either serotonin or catecholamines.(96) 
Indications are that serotonergic neurons may regulate the 
activity of the dopamine system in an inhibitory manner. 
Serotonin has been implicated in a wide variety of important 
physiological processes: sleep, appetite, sexual behaviour 
and control of movement to name a few.(97) 
The 5HT2 -receptors are implicated in psychiatric disorders 
such as schizophrenia, anxiety and depression. 
Head twitches, as seen in 5HT-behaviour syndrome, were 
responsible for the original definition of the 5HT2-receptor. 
Ritansenin, a 5-HT2 antagonist has been reported to exhibit 
anxiolytic effects in humans.(98) 
The 5HT 2C receptors are associated with a variety of 
pathological states, e.g. anxiety, migraine, anorexia 
nervosa. The atypical antipsychotic, clozapine, was shown 
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to have a high affinity for 5-HT2C (greater than that for 5HT2 
or Dopamine (0/02) receptors.)(98) 
Ondansetron a 5-HT 3 antagonist has also been identified as 
a potential anxiolytic.(71) 
The 5-HT 2 receptor has been proposed to be a major site of 
action for atypical antipsychotics. Newer atypical 
antipsychotics were also shown to have an affinity for 5-HT6 
receptors. (99) 
Serotonin is also implicated in the control of circadian 
rhythms. It is speculated that serotonergic innervation of the 
suprachiasmatic nucleus might be involved in the control of 
circadian rhythms. There is however uncertainty whether 
rhythmic activity of the SeN, or the rhythm of 5-HT neuronal 
activity comes first.(1 00) 
Studies indicate that L-5HTP (L-5-hydroxytryptophan) exerts 
its effect on 5-HT levels via a receptor which is distinct from 
those reported previously.(1 01) 
5HT1A receptors have been shown to be located on cell 
bodies of serotonin containing neurons and that activation of 
these receptors reduces not only firing rates of 5-HT 
neurons but also inhibits the release of 5-HT.(1 02) 
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5HT1B and 5HT1D are both involved in feedback control of 
5-HT -release. (97) 
3.7.2.4 Miscellaneous 
Studies investigating the correlation between 
5-hydroxyindoleacetic acid(5-HIAA) and homovanillic acid 
(HVA) in animals indicate that serotonin has a facilatory 
effect on indices of dopamine turnover in especially the 
brain stem and the hypothalamus. The effect of morphine 
on dopamine neurons in the nucleus accumbens was also 
inhibited by stimulation of serotonin receptors by 
fenfluramine (a serotonin releaser) and 
m-chlorophenylpiperazine (an agonist).(1 03) 
Fenfluramine releases endogenous serotonin - its effect is 
blocked by p-chlorophenylalanine (pCPA).(1 04) It was also 
shown that fenfluramine could stimulate the pineal 
N-acetylserotonin and melatonin synthesis.(1 05) 
3.7.3 Melatonin 
3.7.3.1· Melatonin receptors 
Melatonin has been discribed as an omnipresent hormone -
widely distributed and affecting many organs. It has been 
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found that melatonin is not only found in cytosol but also 
located in the nuclei of cells. There is also speculation that 
melatonin acts as a free radical scavenger tl1at protects 
DNA from damage. The fact that a pinealectomy does not 
abolish melatonin totally, suggests that peripheral tissue 
(retina, gut) may produce basal melatonin, whereas the 
pineal gland produces circadian rhythmic melatonin.(1 06) 
Like all hormones, melatonin acts through specific 
receptors. Autoradiographic analysis with 12!il-melatonin 
showed that the density of melatonin receptors varies with 
species and location. Melatonin receptors on membranes 
interact with intracellular second messengers to affect cell 
functions. Melatonin inhibits cAMP in various tissues. It 
also inhibits cAMP, cGMP, diacylglycerol acc:ummulation in 
the anterior pituitary and arachidonic acid re ease from the 
pineal gland.(1 07) 
Melatonin binding sites are high affinity sites with low 
picomolar range Kd-values. Indications are that they are 
G-protein coupled receptors. Inhibition of ccilcium influx and 
membrane potentials (in the Pars distalis) also seem to be 
of importance in mediating melatonin's effect.(1 08) 
The Pars tuberalis of sheep was shown to bl~ an acceptable 
model for studying melatonin receptors. Tryptophan, and 
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other indoles also exhibits weak affinity for the melatonin 
receptor. Treatment with GTPyS (guanine nucleotide) did 
not change the Kd for the melatonin receptor and studies 
with saturation curves showed that an apparent decrease in 
receptor numbers occurs as a result of a shift of the total 
receptor population from a high to a low affinity form. From 
this it has been concluded that the melatonin receptor is a 
member of membrane bound receptors linked through a 
G-protein.(109) 
Melatonin receptors may exist in two states both with 
pM-affinities. 
* High affinity: 10 - 100pM 
* Low affinity: 300 - 800pM 
Binding to both the above is reversible and saturable. 
In hamsters whole brain membranes, a melatonin binding 
site with nM affinity and different pharmacological and 
binding traits than those of the pM-affinity site, were 
identified. 
ML-23 [N - (3,5 dinitrophenyl) - 5 methoxytryptamine] is a 
potent antagonist of melatonin mediated inhibition of the 
release of dopamine from the rat hypothalamus.(11 0)(111) 
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Melatonin and melatonin agonists inhibit dopamine release 
from the retina through activation of a different receptor than 
the serotonin receptor. These effects are antagonized by 
the melatonin receptor antagonist Luzindole 
(N-0779).(112)(113) 
1251-melatonin binding sites are abundant. Only those in the 
hypothalamus, medulla, pons and hipocampus exhibit 
diurnal variation. Timed coincidence of hormone and 
receptor may determine melatonin response .. (11 0) 
In defining a specific hormone receptor it is important to be 
able to measure a specific physiological response triggered 
by receptor activation.(114) 
See tables 5(124) and 6(114) Fig. 10(114) 
Such responses are melatonin's ability to: 
* Condense pigment granules in skin melanophores 
* Inhibit dopamine release in the retina 
* Affect production of cAMP 
These responses were used to develop in vitro bioassays for 
melatonin.(114) 
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TABLE 4 Pharmacology and distribution of melatonin binding sites (124) 
~12511 - IMEL binding 
Affinity 
ML-Receptor (picomolar affinity) 
High 
Kd 10-100 pM 
Sodium 
Magnesium 
Calcium 
Inhibited 
Increased or no effect 
Increased or no effect 
Guanine Nucleotides Inhibited 
Pharmacology 
Localization 
Cellular Function 
Abbreviations: 
21MEL 
MEL 
6 CLMEL 
60 CH3 MEL 
NAS 
5HT 
IPL 
SCN 
PVNT 
PT 
DA 
LUZ 
21MEL - MEL - 6CIMEL> 
>60CH3MEL >NAS .::LUZ»>5HT 
IPL rabbit and chicken retina 
SCN; PVNT; PT of rodents 
chicken brain areas 
Inhibition DA release in retina 
Regulation of circadian rhthyms 
2-iodomelatonin 
Melatonin 
6 Cloromelatonin 
6 Methoxymelatonin 
N-Acetylserotonin 
Serotonin 
Inner plexiform layer 
Suprachiasmatic nuclei 
Paraventricular nucleus 
Pars tuberalis 
Dopamine 
Luzindole 
ML-2 Site (nanomolar affinity) 
Low 
300-800 pM 1 -5 nM 
No effect 
Slight inhibition 
No effect 
No effect 
21MEL - 6CIMEL - 60CH3MEL 
.::MEL - NAS » LUZ > 5HT 
Hamster brain 
Not known 
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Table 5 Pharmacology of functional melatonin receptors (114) 
Inhibition of DA release Pigment condensation 
Rabbit retina Chicken retina Frog skin Isolated frog melatonin 
AGONISTS IC50(nM) ICso(nM) MEC(1)(nM) ICso(nM) 
2-Chloromelatonin 0.0003a 
2-lodomelatonin 0.005 0.01 0.0006a 
2-Methyl-6, 7 -dichloro- 0.01 
melatonin 
6-Choromelatonin 0.04 0.5 
Melatonin 0.04 1.0 005 0.003 
0000009 
5-Methoxyluzindole 1.3(2) 
6-Mehtoxymelatonin 1.6 100 
6-Hydroxymelatonin 2.0 30 0.1 43 
N-acetyltryptamine 5.0(2) >1000 N.E(3) 
N-acetyl-5-methoxy- 10.0 860 
kynurenamine 
N-acetylserotonin 54.0 300 50,000(2) 860 
5-Methoxytryptami ne 63.0 200 700 86 
5-Methoxytryptophol 4000 >10,000 430 
Serotonin >1000 >10,000 N.E. 860 
Luzindole >10,000(3) 
ANTAGONISTS Ka(nM) Ka(nM) 
5-Methoxyluzindole 0.063 
N-acetyltryptamine 9.0 33 +(5) 
Luzindole 20.0 
N-acetylserotonin N.E(4) + N.E 
(1) Minimal effective concentrations 
(2) Partial agonist 
(3) Antagonist 
(4) Not effective 
(5) Antagonized the effect of melatonin but KB not determined 
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3.7.3.2 Melatonin: Miscellaneous 
5-Hydroxytryptophan administered to sheep during daytime 
caused elevated serum melatonin levels (sevenfold) within 2 
hours. This may form the basis for a nonneural pineal 
function test in humans. 
As 5-Hydroxytryptophan is used for depression and 
myoclonus, elevation of melatonin levels induced by 5-HT 
may also be useful in predicting which patients will respond 
to 5-Hydroxytryptophan; it could indicate the ability of the 
pineal gland to convert 5-Hydroxytrytophan to 
melatonin.(115) 
It was shown that the amplitude of the melatonin rhythm in 
humans was diminished while exposed to light and 
deprived of food during the night. This environmental 
influence needs further investigation in humans.(116) 
High doses of propranolol (120-1280mg /day) 
decreased the output of urinary melatonin which may 
reflect a decrease in melatonin production.(116) The 
synthesis of melatonin is stimulated by drugs (eg. dopamine; 
tyramine) that are structually related to noradrenaline.(117) 
(118) 
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Electroconvulsive therapy (ECT) did not seem to induce 
melatonin production. (116) 
It has also been shown that intraperitoneal injection of 
melatonin to rats is followed by a rise of brain serotonin. 
The mechanism of this response is not clear.(119) 
Ethanol, as ingested socially, inhibits natural melatonin 
secretion and increases plasma noradrenaline levels - thus 
interfering with endogenous rhythms.(123) 
Melatonin's possible influence on striatal dopaminergic 
function was also demonstrated insofar that melatonin 
inhibits turning behaviour induced by apomorphine in rats. 
(66)(120) 
Mounting evidence supports the theory that melatonin might 
be involved in all the major neuroendocrine functions of the 
pineal gland for example, similarities between the 
antigonadal and antithyroid effects of melatonin are also 
emerging.(121 ) 
3.7.3.3 Exogenous melatonin in humans 
It is speculated that the increase in melatonin secretion due 
to neuroleptic medications may protect the patient against 
drug-induced parkinsonism by indirectly augmenting 
dopamine activity. Indirect evidence suggests that 
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melatonin acts as a 5-HT2-receptor agonist in physiological 
concentrations - at higher concentrations melatonin 
appears to act as a 5-HT 2-receptor antagonist. 
Circadian dopamine activity and the circadian response of 
schizophrenic patients to neuroleptics may be explained by 
the modulation of dopamine activity via the 5HT2-receptor by 
melatonin.(122) 
3.7.4 Discussion 
The literature search supports melatonin's possible 
involvement in the pathophysiology of anxiety. There seems 
to be a complex interaction between melatonin and various 
neu rotransm itters. 
Evidence points towards a special relationship between 
serotonin and melatonin. Not only is serotonin a precursor 
in melatonin's production, but the constant pineal content of 
serotonin is secured and protected. 
Serotonin may also playa role in the regulation of the 
circadian rhythm via control of the SCN. See fig 10. 
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CHAPTER 4: EVALUATION OF MELATONIN AS AN ANXIOLYTIC 
4.1 Introduction 
Many definitions of anxiety exist. Anxiety is differentiated from 
fear - anxiety referring to an anticipated subjective danger, fear 
to an immediate objective threat.(126) 
A variety of rating scales for anxiety exist.(127)(128)(129) 
Although these scales are not for diagnostic purposes it is 
important to note whether pathological anxiety in patients not 
necessarily suffering from anxiety disorders, changes over time. 
In clinical practice the separation of anxiety from other emotions 
may be difficult. The Hamilton A anxiety rating scale was 
chosen for this trial because of the trialist's clinical experience 
with this particular rating scale. 
It is clear from the literature that anxiety has a complex 
pathophysiology. Multiple neurotransmitters and receptors are 
involved. Anxiety may bear a relationship to central catechol-
amine hyperactivity. The combination of central and peripheral 
catecholamine turnover may reflect a coping response to 
various endogenous and exogenous stimuli.(12S) 
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Postulations that anxiety disorders and depression may be due 
to dysfunctional 5HT1A autoreceptors in different areas of the 
brain have been made. Others are of the opinion that anxiety 
and depression may be different expressions of the same 
underlying disorder.(5) Medications with different modes of 
action are used to alleviate anxiety. 
Different augmentation strategies in the treatment of depression 
are known. This underscores the complex nature of psychiatric 
disorders. It would thus be reasonable to investigate the 
anxiolytic effect of melatonin in humans as melatonin is 
tolerated well by humans and there is no known toxicity.(130) 
Anxiolytic properties of melatonin were demonstrated in mice, 
but research regarding the anxiolytic properties of melatonin in 
humans is lacking.(3) 
This could serve as a pilot study for further investigations 
regarding the use of melatonin in clinical psychiatry. 
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4.2 Protocol 
Each patient completed an "N of 1" randomized double blind 
placebo controled trial.(131) A 3mg melatonin tablet 
(Melapure™, Genzyme Pharmacenticals, USA) or a placebo 
(Gelatine capsule fillied with starch) were administered at 
21 hOD during Pair 1 and Pair 2 of the trial as indicated in 
Table 6. 
A sample of 30 adult patients suffering from anxiety was 
selected to participate in the trial. See Table 7 for patient 
profiles. The trialist obtained written informed consent from 
subjects before the trial commenced. (According to guidelines 
from the Medical Association of South Africa Research Ethics 
Committee.) 
The complete protocol, which was approved by Rhodes 
University ethical committee, is attached as part of the 
appendix. The protocol complies with the principles expressed 
in the Declaration of Helsinki. 
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A sample of the melatonin tablets (Melapure TM) which were 
used in this study was analysed by means of TLC to ensure that 
they contain melatonin and that there were no other metabolites 
or impurities in them. Another "over the counter" product 
(Melatonin, Schiff Products, Salt Lake City) was analysed by 
means of UV absorbance readings and HPLC. (See appendix). 
This was done to evaluate melatonin content of "over the 
counter" melatonin products. It was revealed after conclusion 
of the experiment that M1 was the melatonin and M2 the 
placebo. 
4.3 Statistical data analysis: Discussion 
The data in this analysis have been obtained from 30 patients 
who completed a baseline Hamilton A anxiety scale, and at the 
end of each of four treatment sessions (Table 8). Patients 5, 11 
and 13 did not complete the experiment as indicated in Table 8. 
The questionnaire was the same for each session and 
consisted of 14 questions each on a five point scale each 
starting with 0 (anxiety absent) up to 4 (very severe anxiety). 
Table 6 An liN of 1" Randomized double blind, placebo contioUed tilal of melatonin as an anxioiyiic. 
<:-------------------- F'Clir 1. ------------------:> <:---------------------- F'Clir 2. ----------------------:> 
DClys 1 234 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 
F'Cltient 1 F'1 F'1 WOF'. F'1 F'2 WOF'. F'2 F'1 WOF'. F'2 F'2 
<-----M 1M -----1 2 <:-------M 1M -------:> 1 2 <:------M 1M ------:> 1 2 <:------M/M2-----:> 
F'Cltient 2 :> 
I I I I I I I I 
I I I I I I I I 
F'Cltient 30 
* MelCltonin Cldministered in double blind, plClcebo controlled experiment during F'Clir 1 & F'Clir 2. (M/M2) 
* F'1 F'1 = F'Clir 1 (fJeriod 1) I F'1 F' 2 = F'Clir 1 (fJeriod 2) 
* WOF' = WClsh-Out F'eriod 
* F' 2F' 1 = F'Clir 2 (fJeriod 1) I F' 2F' 2 = F'Clir 2 (Period 2) 
27 
= N of 1 
= N of 1 
I i 
I 
= N of 1 : 
! 
0'1 
0'> 
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TABLE 7 Patients Profiles 
Subject Age Sex Diagnosis Medication Duration of Severity of 
(Years) Illness Social 
(years) stressors 
(0-3) 
1 48 Female Major Depression Citalopram 20mg daily 27 3 
2 38 Female Borderline Personality Fluvoxamine 100mg 20 2 
disorder I Substance daily 
abuse 
3 41 Male Major Depression Paroxetine 20 mg daily 9 3 
4 56 Female Generalized anxiety Buspirone 5mg twice 46 3 
disorder I Major daily I Amitriptyline 
Depression 100mg daily 
5 36 Female Major Depression Fluoxetine 20mg daily 5 3 
6 55 Male Generalized anxiety Buspirone 5mg twice 15 1 
disorder daily 
7 47 Female Major Depression Moclobemide 150mg 20 1 
twice daily I 
Flupenthixol 0,5mg 
twice daily 
8 39 Female Major Depression Fluoxetine 20mg daily 9 3 
9 37 Male Histrionic personality Perphenazine 4mg 20 2 
disorder twice daily I 
Amitriptyline 75mg 
'I 
twice daily 
I 
10 44 Male Schizophrenia Clozapine 150mg daily 27 2 
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Subject Age Sex Diagnosis Medication Duration of Severity of 
(Years) Illness Social 
(years) stressors 
(0-3) 
11 48 Female Post - Traumatic Amitriptyline 50mg 9 months 1 
Stress disorder daily I Perphenazine 
4mg twice daily 
12 53 Female Panic Disorder Sertraline 50mg daily 33 2 
13 61 Female Major Depression Amitriptyline 25mg 2 1 
daily 
14 40 Female Obsessive compulsive Citalopram 40mg daily 28 3 
disorder 
15 45 Male Major Depression Trazodone 300mg 10 1 
daily 
16 25 Female Major Depression Sertraline 50mg daily 2 1 
17 60 Female Major Depression Sertraline 50mg daily 3 2 
18 54 Female Dysthymia Clomipramine 75mg 1 3 
daily 
19 33 Male Social Phobia Moclobemide 300mg 15 2 
twice daily 
20 29 Female Major Depression Fluvoxamine 100mg 1 2 
daily 
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Subject Age Sex Diagnosis Medication Duration of Severity of 
(Years) Illness Social 
(years) stressors 
(0-3) 
21 49 Male Panic Disorder Fluoxetine 40mg daily 40 1 
I Amitriptyline 75mg 
twice daily 
22 43 Male Adjustment disorder Nil 5 months 3 
23 54 Female Major depression in Nil 5 1 
Partial Remission 
24 42 Female Major Depression Fluoxetine 60mg daily 8 2 
25 47 Female Major Depression Nil 1 month 3 
26 45 Male Major Depression Lithium 250mg 3 times 3 3 
daily I Imipramine 
200mg daily I 
Thioridazine 150mg 
daily 
27 43 Female Major Depression Mianserin 90mg daily I 30 3 
Thioridazine 75mg 
daily 
28 64 Male Schizo affective Mianserin 120mg daily 50 1 
disorder I Chlorpromazine 
75mg daily 
29 42 Male Borderline personality Imipramine 200mg 22 2 
disorder daily 
30 45 Male Bipolar mood disorder Lithium 1350mg daily 25 2 
Patient Base line 
Day 0 
1 I 23 
2 17 
3 22 
4 34 
5 27 
6 16 
7 18 
8 34 
9 44 
10 19 
Table 8 Data Sheet: Hamilton A anxiety scores 
P1P1 P1P2 P2P1 P2P2 
Day 6 Day 13 Day 20 Day 27 
26 20 31 22 
11 16 16 11 
6 10 2 0 
32 20 14 4 
16 28 withdraw re' pneumonia 
10 6 6 7 
19 10 11 10 
" .... 29 28 28 .)/ 
44 40 33 31 
16 14 3 0 
-- -_ .. _------
(J) 
o 
Table 8 Data Sheet: Hamilton A anxiety scores 
Patient Base line P1P1 P1P2 P2P1 P2P2 
11 32 32 34 34 withdraw re' 
depression 
12 14 8 17 10 9 
13 23 20 20 withdraw re' flu 
14 25 26 39 32 22 
15 34 35 28 22 15 0> ....Jr.. 
16 15 15 17 15 22 
17 44 29 32 26 24 
18 21 16 14 11 12 
19 30 24 22 19 12 
20 22 17 19 14 12 
Patient Base line 
21 , 33 
22 27 
23 10 
24 46 
25 24 
26 56 
27 43 
28 28 
29 23 
30 10 
Table 8 Data Sheet: Hamilton A anxiety scores 
P1P1 P1P2 P2P1 
22 14 8 
27 30 29 
17 13 4 
50 41 41 
16 9 14 
56 56 53 
46 34 29 
23 1 1 5 
20 23 16 
6 3 6 
P2P2 
5 
30 
4 
41 
8 
49 
23 
4 
24 
6 
(j) 
N 
63 
Once the code was broken it transpired that the initial treatment 
(M1) consisted of melatonin administration and that the 
decrease in the mean score for this initial period was significant. 
However, the decrease in the mean score was also significant 
during the last period when treatment M2 was administered. It 
is likely that some other factor caused the continued decrease 
in the mean scores. 
A graphical representation of the median, quartiles and 
variation of each response is given in the graph below. (Fig 12)· 
t-Tests for dependent samples 
A cross comparison of all responses by using a t-test will reveal 
the statistically significant differences between each possible 
pair of mean scores. The data satisfies the requirements to 
make such a t-test valid. (Table 9(b)) 
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TABLE 9(a) Descriptive statistics 
Score N Mean Median minimum maximum Lower Upper Std.Dev Skewness 
Quartile Quartile 
Base 30 27.1 24.5 10 56 18 33.5 11.23 0.707 
P1P1 30 24.1 21 6 56 16 30.5 12.88 0.836 
P1P2 30 22.3 20 3 56 13 29.5 12.14 0.786 
P2P1 28 19 15.5 2 53 9 29 12.85 0.752 
P2P2 27 16.1 12 0 49 6 24 12.45 0.909 
30 -
Significant I Non-Significant I Significant Significant 
decrease I decrease I decrea"e decrea~e I 
I I 
25 - -- - - - - - - -1- ---------- - - - - - I-- I 
Q) 
I I I "-0 u 
(J) I C I 0\ 'JI 
ro I I I Q) ~ 20 
--- - I 
-! I 
I I I 
I Ml M2 I Ml M2 
15 J 1 I I ---J.__ 
8ase_L P1P1 P1P2 P2P1 P2P2 
Measure 
-";,-~ .". - 'n;- ~ ~.~ -~j,..." ':~h - r-"....r --t ~!9 : :-'"-. grcpl Iva. "" ...... mpOi ,S...In 01 LI ,e mean S",I..I; e;::, CI 
each evaluation. 
66 
- -, - -r-
: 
--
~ GO c 
50 
40 
--, 
(/) 
••• 
~ 30 
0 
u !~(f) LO 
.1 ::r::: Min-Max 10 
r'i'.t'l.:I 25%-75% 
o Median value P2P2 P1'P2 P2P1 u - - SE L P1P1 
BA - luations. 
Fig -12 
45 
40 
-
2:: 35 
Q> 
o 
~ 30 
Fig 13 
Box an d Whisker plot of eva 
-
Mild 
-------===. 1'1'221>2 
Moderate 
Social Stress 
e in baseline sc Decreas 
social stress. 
1'21'1 
1'11'2 
1'11'1 
function of ore as a 
67 
liN of Oneil results 
If a single patient obtains a Hamilton A score lower than his/her 
base line score in both periods when melatonin was 
administered, then we accept that melatonin was anxiolytic for 
that patient. Of the 27 patients who completed the full trial, 15 
patients had lower scores than their baseline scores in both 
period 1 and period 2 for the M1 treatment. Similarly, 20 
patients had lower scores in both periods for the M2 treatment. 
A contingency table summarizing these scores is given in 
Table 10. 
To investigate whether sub-groups of patients can be identified 
who had higher rates of success, the base line scores can be 
categorized in four groups where each group contains 
approximately the same number of patients. The number of 
patients who improved twice in succession for a given treatment 
can then be identified and a possible trend can be investigated. 
The observed success rate for the patients in the two lower 
categories of the baseline score is somewhat higher than for 
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TABLE 9(b) t-scores with associated p-values 
Base line P1P1 (M1) P1 P2 (M2) P2P1 (M1) P2P2 (M2) 
X = 27.13 X = 24.07 X = 22.18 X = 19.00 X = 16.11 
Base line 3.07 3.74 5.21 5.99 
(0.0046)* (0.0008) (0.00002) (0.000003) 
P1 P1 (M1) 1.44 4.09 4.93 
(0.160) (0.00035) (0.00004) 
P1 P2 (M2) 3.57 4.80 
(0.001 ) (0.000056) 
P2P1 (M1) 2.77 
(0.010) 
* p-values are given in brackets. P-values below 0.01 are an indication of a significant 
difference between the mean values of the relevant responses. 
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the other two groups. For this sample size, it cannot be proved 
that this effect is statistically significant (p- value=O.156) 
A similar comparison on treatment M2 reveals that the 
observed success rate for treatment M2 is higher than for the 
treatment M1 for the patients in the two higher categories of the 
baseline score. Once again, this trend cannot be proved to be 
statistically significant (p-value=0.457). See tables 11/12. 
Correlation between social stress and Hamilton score 
To test whether the average decrease in the Hamilton score 
was related to the level of social stress the individual patients 
experience, the patients were categorized in three categories of 
social stress: (1) none to mild, (2) moderate and (3) severe. An 
analysis of variance (AN OVA) with social stress as an 
explanatory variable and each Hamilton score as response 
variable was carried out. There is no evidence in this sample 
that the reduction in the Hamilton score was correlated to social 
stress. 
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It appears that each catagory of social stress benefitted equally 
from the treatment. Fig 13. 
To investigate possible correlations between the level of social 
stress and the patient's response on each item, Chi- squared 
tests on the relevant contingency tables were carried out. None 
of these correlations proved to be statistically significant. For 
example, see the contingency table relating level of social 
stress to patient's response on item 4 (ability to sleep). 
(Table 13) 
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TABLE 10 Contingency table comparing treatment with the success rate 
Success rate 
Treatment Not successful Successful Total 
M1 12 15 27 
M2 7 20 27 
Total 19 35 54 
TABLE 11 Contingency table comparing baseline categories with the 
success rate of treatment M1 
M1 
Base line Categories Not successful Successful Total 
0-18 3 4 7 
19 - 24 1 6 7 
25 - 33 3 3 6 
34 - 56 6 2 8 
Total 13 15 28 
TABLE 12 Contingency table comparing baseline categories with the 
success rate of treatment M2 
M2 
Base line Categories Not successful Successful Total 
0-18 3 4 7 
19 - 24 1 6 7 
25 - 33 2 3 5 
34 - 56 1 7 8 
Total 7 20 27 
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TABLE 13 Contingency table comparing social stress with improvement 
of sleep 
Ability to sleep 
Level of social stress Improved Did not change Worsened Total 
Mild 6 3 a 9 
Moderate 5 2 1 8 
Severe 6 4 1 11 
Total 17 6 5 28 
* Fisher's exact test gives a p-value of 0,9685. 
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Conclusion 
Although the treatment of the patients was successful, it could 
not be statistically shown whether this was due to the melatonin 
or the placebo. It is possible that apart from a placebo effect, 
the initial melatonin administration (M1) introduced a phase shift 
in the patient's melatonin phase response curve that could 
explain the sustained improvement in the patients' anxiety 
levels during period two of pair two (placebo, M2). 
Other factors that may be responsible for the sustained 
improvement are a placebo effect or a therapeutic response 
due to prolonged contact with a clinician. Further studies are 
needed to elucidate melatonin's role in anxiety. From this study 
it may be concluded that: 
a) Anxiety levels and social stressors do not correlate with 
the improvement of anxiety associated with the use of 
melatonin. 
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b) That a liN of 1" study is not an appropriate study design for 
investigating melatonin's anxiolytic effects as it does not 
take a possible melatonin phase shift into account. 
c) Melatonin phase response curves should be estimated in 
each patient before and after initiating melatonin 
treatment to correlate anxiolytic effect with shifts in 
melatonin's phase response curves. 
d) That non-invasive measures of melatonin levels (saliva / 
urine) need to be evaluated for clinical research. 
e) Over the counter melatonin products content correlates 
well with pure melatonin and is relatively easy to verify. 
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APPENDIX 
1. Protocol 
2. Informed consent 
3. Format of physical examination 
4. Hamilton A - anxiety scale 
5. Analysis of melatonin tablets 
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PROTOCOL 
TRIALlST: JOHANNES JACOBUS McCALLAGHAN 
PROJECT: MASTER OF SCIENCE (PHARMACY) IN THE 
SCHOOL OF PHARMACEUTICAL SCIENCES. 
UNIVERSITY: RHODES UNIVERSITY 
PROMOTOR: PROF B POTGIETER 
TITLE: MELATONIN AS AN ANXIOLYTIC: AN INVESTIGATION 
INTO THE INTERACTION OF MELATONIN WITH 
SEROTONIN RECEPTORS. 
PROTOCOL NO: RHODES/PHARM:1 
TRIAL DESIGN: DOUBLE BLIND, PLACEBO CONTROLLED, EACH 
PERSON COMPLETING A " N OF 1 " STUDY. 
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RHODES UNIVERSITY 
SCHOOL OF PHARMACEUTICAL SCIENCES 
PROTOCOL FOR CLINICAL WORK 
1. SPECIFIC AIMS AND OBJECTIVES 
a) To conduct a literature search on the anxiolytic properties of 
melatonin with emphasis on the use of melatonin in humans. 
To seek evidence from the literature that melatonin interacts 
with serotonergic receptors and to propose further investigation 
in this regard. 
b) Conduct a pilot study evaluating the anxiolytic properties of 
melatonin in humans. 
c) Generate ideas for further studies on the posssible role of 
melatonin in psychiatric disorders. 
d) Publish the results in a scientific journal. 
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SIGNIFICANCE AND BACKGROUND INFORMATION 
Melatonin is secreted by the pineal gland in a rhythmic fashion with high 
levels during night time.The pattern of melatonin secretion in an 
individual is known as its Phase Response Curve. Evidence suggests 
that shifts backwards or forwards of this Phase Response Curve might 
be the basis of melatonin's involvement in psychiatric disorders. 
Melatonin is safe to administer to humans. A person receiving 200mg 
melatonin intravenously daily for 5 days showed no evidence of delayed 
toxicity 18 years later. 
Researchers were unable to find an oral LD-50 for melatonin for rats. 
It was also found that melatonin was not mutagenic in standard in vitro 
tests. Clinical trial certificates have been issued to cover long term 
administration of up to 300mg of melatonin per day. 
Drowsiness has frequently been reported with low doses of melatonin, 
but doses in the range of 50mg - 6.6g melatonin per day have also given 
rise to complaints of headaches and abdominal cramps. 
The use of melatonin in preventing jet lag is well known. Melatonin, 
however, shares pharmacological properties with the benzodiazepines -
anticonvulsant, muscle relaxant, sedative-hypnotic and anxiolytic. 
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The anxiolytic properties of melatonin have been poorly documented 
other than in studies on the rat. 
Melatonin is currently available in South Africa as a health product at 
pharmacies and health shops. 
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EXPERIMENTAL DESIGN AND METHOD 
* Each subject will undergo an " N OF 1 " study in a double blind 
placebo controlled study. 
* Each subject will be examined for exclusion criteria and informed 
consent will be obtained. 
* Information will be gathered by means of the Hamilton A evaluation 
forms. 
* Subjects will not be hospitalized and visits will be arranged according 
to the research schedule. 
* The experimental population will consist of adults complaining of 
anxiety. They would be referred by doctors, psychologists,pharmacists 
and clinics for participation in the trial. 
* INCLUSION CRITERIA 
- older than 21 years of age. 
- complaining of anxiety. 
- no history! physical evidence of liver or kidney disease. 
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- must be able to give informed consent. 
- participate in trial out of own free will. 
* EXCLUSION CRITERIA 
- younger than 21 years of age. 
- not mentally competent to give informed consent(mentally retarded}. 
- if physical examination reveals evidence of liver or kidney disease. 
- pregnancy/non use of contraceptives in females. 
- not willing to participate in trial or if subject should wish to end 
his/her participation. 
Subjects will undergo a physical examination and urine dipstick 
evaluation by a medical doctor (the trialist) before commencement 
of the trial. Female subjects will also undergo a pregnancy test. 
No invasive investigations will be done during the trial and there will 
be no restrictions on diet. 
Patient files will not be consulted. Evaluation will consist of history 
and physical examination. 
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Evaluation will be by means of the Hamilton A Rating Scales 
according to the research schedule. 
A pharmacist will dispense melatonin and placebo for the purpose 
of the double blind study. 
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DATA MANAGEMENT 
Hamilton A rating scales will be tabulated - see data sheet. 
DATA ANALYSIS AND PRESENTATION 
This will be a double blind placebo controlled experiment. Each patient 
will complete an " N of 1 "study. This will enable the researcher to 
evaluate the efficacy of melatonin as an anxiolytic in individual patients. 
The Fischer exact test will be used to evaluate melatonin's effect as an 
anxiolytic on the whole research population (i.e. is there a statistically 
significant decrease in the anxiety levels experienced by patients with 
the use of melatonin). 
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SECTION 2 
HUMAN SUBJECTS. 
1. CHARACTERISTICS OF SUBJECT POPULATION 
30 adult subjects between 21-60 years of age. No clinical evidence 
of renal or liver ailments. No exclusion criteria with regards to 
gender or race. Estimate female/male ratio 60:40 (on grounds of 
ratio seen in clinical practice). 
2. SOURCE OF RESEARCH MATERIAL 
Patients are referred by doctors, pharmacists, psychologists or 
clinics. No medical/personal files will be consulted. Information will 
be obtained by means of an interview (history), physical examination 
(appropriate urine analysis) and the Hamilton A anxiety scale. 
3. RECRUITMENT OF SUBJECTS 
Each subject will be personally informed of the research proposal, 
its aims and risks and the involvement of the trialist. Please see 
patient information leaflet/consent form. 
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4. POTENTIAL RISKS 
As a low dose (3mg) of melatonin is to be used sedation should be 
expected. Patients need to be warned against driving, working with 
dangerous machinery and interaction with other sedating 
substances. If a patient suffers from depression he may experience 
an increase in depression. Disappointment due to no improvement 
in anxiety levels may be seen as a psychological risk and needs to 
be addressed during informed consent. Social and legal risks can 
be minimized by confidentiality and by obtaining informed consent. 
5. PROTECTION AGAINST AND MINIMIZING POTENTIAL RISK 
A thorough evaluation (physical/history) before the clinical trial will 
be conducted. The trialist (a medical doctor) will be available to 
attend to any complaints. The trialist will be the only person 
physically involved in conducting the trial - thus minimizing risk of 
breach of confidentiality. 
The data sheet will contain no identification information to ensure 
anonymity. 
The trialist is insured by the Medical Defence Union and legal 
advice can be obtained if needed. 
86 
6. RISKS TO SUBJECTS 
Melatonin is used world wide in clinical trials. It was found to be 
safe without serious side effects - although depression might 
exacerbate. Subjects will be informed that no benefit during the pilot 
study must be expected as this serves only to develop a research 
strategy for future studies on the clinical use of melatonin. 
SECTION 3 
This will serve as a pilot study in which a research strategy will be 
developed. This will serve as a basis for studies towards a Ph.D. 
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PATIENT INFORMATION LEAFLET 
TRIAL TITLE: Melatonin as an anxiolytic: An Investigation into 
the interaction of melatonin with serotonin 
receptors. 
Clinical Trial Number: Rhodes / Pharm: 1 
INTRODUCTION 
You are invited to volunteer for a research study. You have been 
asked if you would be willing to take part in this trial. This information 
leaflet is to help you to decide if you would like to participate. Before 
you agree to take part in this study you should fully understand what 
is involved. If you have any questions which are not fully explained in 
this leaflet, do not hesitate to ask the investigator. You should not 
agree to take part unless you are completely happy about all the 
procedures involved. In the best interests of your health it is strongly 
recommended that you discuss with or inform your personal doctor of 
your possible participation in this study. 
WHAT IS THE PURPOSE OF THIS TRIAL? 
You are complaining of anxiety and the investigator will ask you to 
consider taking part in research to investigate the anxiolytic effects of 
melatonin. 
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This is a research project to develop further plans on how to use 
melatonin in patients suffering from anxiety - do not see participation 
as treatment for your anxiety. During the study you will receive 3mg 
melatonin at night (9pm) and an inactive substance (called a placebo) 
in such a way that neither yourself nor the investigator will know 
which one you are receiving. This is done to evaluate the true effect 
of melatonin. 
WHAT IS THE DURATION OF THIS TRIAL? 
If you decide to take part you will be one of 30 patients. The study will 
last for up to one month. You will be asked to visit the investigator 
once per week. 
On the first visit you will undergo the following: 
1. Hamilton A evaluation 
2. General physical examination, urine dipstick and a pregnancy 
test if applicable. 
3. Interview (including detailed medical/psychiatric history). No 
personal/medical files will be consulted. 
On each follow-up visit a Hamilton A evaluation will be 
conducted. 
(Please see appendix). 
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It is important that you let the investigator know of any 
medicines (both prescriptions or over-the-counter medicines), 
alcohol or other substances that you are currently taking or if 
you are a blood donor. 
HAS THE TRIAL RECEIVED ETHICAL APPROVAL? 
This clinical trial protocol was submitted to the Rhodes University 
ethics committee and written approval has been granted by the 
committee. 
WHAT ARE MY RIGHTS AS A PARTICIPANT IN THIS TRIAL? 
Your participation in this trial is entirely voluntary and you can refuse 
to participate or stop at any time without stating any reason. Your 
withdrawal will not affect your access to other medical care. The 
investigator retains the right to withdraw you from the study if he 
considers it to be in your best interest. If it is detected that you did not 
give an accurate history or did not follow the guidelines of the trial and 
the regulations of the trial facility, you may be withdrawn from the trial 
at any time. 
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IS ALTERNATIVE TREATMENT AVAILABLE? 
It is important to note that melatonin is not a registered treatment for 
anxiety. Recognized effective medication is available for the 
treatment of anxiety. 
MAY ANY OF THESE TRIAL PROCEDURES RESULT IN DIS-
COMFORT OR INCONVENIENCE? 
No procedures will be done. Only urine dipstick analysis. 
WHAT ARE THE RISKS INVOLVED IN THIS TRIAL? 
All medicines carry some risk, however small. In previous studies 
some patients have reported experiencing side effects which included 
drowsiness, headaches, and abdominal cramps. 
ARE THERE ANY WARNINGS OR RESTRICTIONS FOR MY 
PARTICIPATION IN THIS TRIAL? 
If you are a female who can become pregnant you must use suitable 
contraceptive measures during the trial as the safety of melatonin 
during pregnancy has not been established. Melatonin is not 
implicated in reducing the efficiency of oral or parenteral 
contraceptives. 
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DISCONTINUATION OF TRIAL TREATMENT 
Uncontrolled discontinuation of trial medication is inadvisable. 
Special care needs to be taken for the discontinuation of this trial 
medication. The investigator will supervise any discontinuation with 
your health as first priority. 
INSURANCE AND FINANCIAL ARRANGEMENTS 
The investigator will be available to deal with your complaints relating 
to the trial. Neither you nor your medical aid will be expected to pay 
for these consultations, the melatonin or visits scheduled during the 
trial. As no serious life threatening side-effects were reported with 
low dose melatonin (3mg) the patient would not be entitled to any 
other free medical threatment during participation in this trial. (e.g. 
hospitalization, blood test or medication). 
You must notify the investigator immediately of any complications or 
side effects experienced during the trial. 
You have not waived any of the legal rights that you otherwise would 
enjoy as a participant in this trial by signing this form. 
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You will not be paid to participate in the trial. 
Please note that if you have a life insurance policy you should notify 
the appropriate insurance company concerned of your intention to 
participate in a clinical trial. Our information to date is that it should 
not affect any life insurance policy taken out. Nevertheless you are 
strongly advised to notify the company concerned. 
Any information uncovered regarding your test results or state of 
health as a result of your participation in this trial will be held in strict 
confidence. You will be informed of any finding of importance to your 
health or continued participation in this trial but this information will 
not be disclosed to any third party. The only exception to this rule will 
be cases where a law exists compelling us to report individuals 
infected with communicable diseases. In this case, you will be 
informed of our intent to disclose such information to the authorised 
state agency. 
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INFORMED CONSENT FORM 
I hereby confirm that I have been informed by the investigator, Dr J J 
McCallaghan, about the nature, conduct, benefits and risks of clinical 
trial Rhodes / Pharm: 1. I have also received, read and understood 
the written information (Patient Information Leaflet and Consent 
Form) regarding the clinical trial. 
I am aware that the results of the trial, including personal details 
regarding my sex, age, date of birth, initials and diagnosis will be 
anonymously processed into a trial report. 
I may, at any stage, without prejudice, withdraw my consent and 
participation in the trial. 
I have had sufficient opportunity to ask questions and (of my own free 
will) declare myself prepared to participate in the trial. 
Patient's 
Name 
Patient's 
(Please print) 
Signature ..................... Date ............ .. 
Investigator's 
Name 
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(Please print) 
Investigator's 
Signature .................... Date ............. . 
I, Dr ...................... herewith confirm that the above patient has been 
fully informed about the nature, conduct and risks of the above trial. 
Witness's 
Name* 
Witness's 
(Please print) *Consent procedure should be witnessed 
whenever possible. 
Signature . .............. ..... Date .............. . 
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Patient: .... ....... .... .................. ...... ............. ....... ....... ................. ..... Date: ............................ . 
Age: ........................................................ . Sex: .......................................................... . 
Medication: .............................................. . Allergies: .................................................. . 
History: 
Medical: .............................................................. : ................................................................. . 
.............................................................................................................................................. 
.............................................................................................................................................. 
Surgical: .............................................................................................................................. . 
.............................................................................................................................................. 
Psychiatric: ........................................................................................................................... . 
Physical examination: 
Height: ......................... Weight: ........................ BP: .................................. P: ................... . 
General: .............................................................................................................................. . 
Cardiovascular: ................................................................................................................... . 
Respi ratory: .................................................................... : .................................................... . 
Alimentary + Genito urinary systems: 
Urine dipstick: 
Pregnancy Test (female): .................................................................................................. . 
Nervous system: ............................................................................................................... . 
Accepted for trial: YES NO 
Patient No.: Hamilton A - anxiety scale 
Age: 
Medication: 
I 1 2 L ~ I 4 ~_ I 6 7 I 8 I 9 10 I 11 12 13 I 14 I 15 I 16 I 17 I 18 I 19 I 20 I 21 
DAY o 
1. ANXIOUS MOOD Worries, anticipation of the worst, fearful anticipation, irritability 
2. TENSION Feelings of tension, fatigability, startle response, moved to tears easily, trembling, feelings of restlessness, inability i 
to relax 
3. FEARS Of dark, of strangers, of being left alone, of animals, of traffic of crowds 
4. INSOMNIA Difficulty in falling asleep, broken sleep, unsatisfying sleep and fatigue on waking, dreams, nightmares, nights 
terrors 
5. INTELLECTUAL Difficulty in concentration, poor memory 
(Cognitive) 
6. DEPRESSED MOOD Loss of interest, lack of pleasure in hobbies, depression, early waking, diurnal swing 
7. SOMATIC Pains and aches, twitching, stiffness, myoclonic jerks, grinding of teeth, unsteady voice, increased muscular tone 
(Muscular) 
8. SOMATIC Tinnitus, blurring of vision, hot and cold flushes, feelings of weakness, prickling sensation 
(Sensory) 
9. CARDIOVASCULAR Tachycardia, palpitations, pain in chest, throbbing of vessels, fainting feelings, missing beat 
SYMPTOMS 
10. RESPIRATORY Pressure of constriction in chest, choking feelings, sighing, dyspnoea 
SYMPTOMS 
11. GASTRO Difficulty in swallowing, wind, abdominal pain, burning sensations, abdominal fullness, nausea, vomiting, 
INTESTINAL borborygmi, looseness of bowels, loss of weight, constipation 
SYMPTOMS 
12. GENITOURINARY Frequency of micturition, urgency of micturition, amenorrhea, menorrhagia, development of fragility, premature 
SYMPTOMS ejaculation, loss of libido, impotence 
13. AUTONOMIC Dry mouth, flushing, pallor, tendency to sweat, giddiness, tension headache, raising of hair 
SYMPTOMS 
14. BEHAVIOUR AT Fidgeting, restlessness or pacing, tremor of hands, furrowed brow, strained face, sighing or rapid respiration, facial 
INTERVIEW pallor, swallowing, belching, brisk tendon jerks, dilated pupils, exopthalmos 
Total 
GRADING SCORES (0-4) 
o :Absent 1 :Mild 2 :Moderate 3 : Severe 4 :Very servere 
22 23 24 
6 13 20 
25 26 
27 
27 
<D 
0> 
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A: Thin layer chromatography of pure melatonin (Sigma)and 
Melapure TM) 
Mobile phase - Chloroform: Methanol (9 : 1) 
R = 39/ = 0487 f 80 ' 
•. " 
'. 
1. Pure melatonin dissolved in methanol. 
2. Pure melatonin dissolved in ethanol. 
\ 
f 
3. Melapure™ - Tablets dissolved in chloroform. 
4. Melapure™ - Tablets dissolved in dichloromethane. 
5. Double Spot. 
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B: Ultraviolet Analysis - Absorbance readings at 278nm 
Aim: To determine the melatonin content of Melatonin ™ tablets. 
Experimental procedure: 
a. Made stock solution- of melatonin = 9mg /1 OOml methanol 
b. Made 5 dilutions from the stock melatonin solution with 
methanol: 
O.9mg/100ml, 1.8mg/100ml, 3.6mg/100ml, 
5.4mg/100ml and 7.2mg/100ml 
c. Took absorbance readings of stock solution and 5 dilutions 
of melatonin (against methanol as a blank). 
d. Plotted a calibration curve of concentration of melatonin vs 
absorbance. 
e. Extracted three melatonin tablets (9mg), into chloroform. 
f. Took absorbance reading of extraction (against chloroform 
as a blank) and determined graphically the concentration 
of melatonin extracted from tablets. 
ABSORBANCE READING OF MELATONIN 
Concentration Absorbance 
(mg/100ml) 
0.9 0.235 
1.8 0.43 
3.6 0.863 
5.4 1.271 
7.2 1.675 
9 2.226 
Extraction sample 2.194 
Melatonin concentration extracted from tablets determined 
from the calibration curve = 8.89 mg/100m!. 
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C: HPLC - Analysis 
Aim: To confirm melatonin content of Melatonin ™ tablets. 
Experimental procedure: 
UV - uetector at 278nm. 
Mobile pllase - Chloroform: Methanol (9 : 1) 
a. Made stock solution of pure melatonin (Sigma) = 9mg / 
100ml methanol. 
b. Three melatonin tablets extracted in chloroform. 
c. Injected stock solution and extracted sample to identify 
compound in extraction, using retention times and peak 
shapes for the identification. 
Pure Melatonin in methanol. 
***************~*+~~ ~k**************************************************** ** 
* * 
* TIME: lO:3J dill PELTA CHROMATOGRAPHY DATA SYSTEM DATE: 8/10/98 * 
* AREA PERCENT REPORT * 
*************+-A -1 l -L J /. -1 + :1.:'***************************************************** 
SAMPLE NAME: :;1\MFLl'~ 
SAMPLE TYPE: ,,1\M), 
SAMPLE AMOUNT 1 .00 
DILUTE 1.00 
CHROMATOGRAM FILE: A 
CHROMATOGRAM SOURCE FILE 
METHOD NAME APM 
INJ 1 OF 1 
Chromatogram 1\ t('('otded at 10:16 am on 08/10/98 
Captured using !lI('!'!Jod : INTEGRAT 
r0 
o 
o 
milliVolts ~ 
OJ 
o 
8 
o 
o o· ... -'"---.-.-.-., ~-----~ -~_~-- - ____________ L-______ ----j 
3 0 
:; 
c 
It 
Ul 
N 
o 
._-------_ ....... -.-~-------------.------------
========~~=======~~==~=======~==~==============================~==~========== 
PK# CPT# TYPE COMPONENT NAME RET. TIME WIDTH AREA RESULT 
1 1 PB MELATONIN 1. 46 3.10 1352.9 100.0 
TOTALS : 1352.9 100.0 
===========~==~===~========================================================= 
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Melatonin ™ extraction in chloroform. 
**************************************************************************** 
* 
* TIME: 11:09 am DELTA CHROMATOGRAPHY DATA SYSTEM 
AREA PERCENT REPORT 
DATE: 8/10/98 * 
* * 
**************************************************************************** 
SAMPLE NAME : 
SAMPLE TYPE : 
SAMPLE AMOUNT 
DILUTE 
MELATONIN 
SAMP 
1. 00 
1. 00 
C~ROMATOGRAM FILE : 
CHROMATOGRAM SOURCE 
METHOD NAME 
INJ 
Chromatogram B3 recorded at 11:05 am on 08/10/98 
Captured using method : APM 
~ 
8 
a 
a 
a 
3 I 
~. :-'"~ 
if a i 
, 
I 
.... w milliVolts ()1 
J\) ~ ~ a 
a a b 
B3 
ACQUIRE 
APM 
1 OF 1 
(Xl 
a 
a 
§ 
a 
~ , ----~-----------------~
.ME~TrN_IN ____ --=~~~~~~----------------------------------------------l 
I 
I 
I 
I 
I 
================================================================:============ 
PK# CPT# TYPE COMPONENT NAME RET. TIME WIDTH AREA RESULT 
1 1 BE MELATONIN 1. 46 6.70 7887.0 100.0 
TOTALS : 7887.0 100.0 
==============================================:====~============~====~;====== 
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Stripchart plot for overlay. 
DELTA CHROMATOGRAPHY DATA SYSTEM TIME - 11:15 am DATE - Thu Oct 08 1998 
STRIPCHART PLOT FOR OVERLAY 
======~================================~~===============~===~================ 
~ 
b 
gJ 
CD 
b 
milliVolts ~ § 
b 
g+I~--------~----------~--------~----------~----------r 
I 
I 
I 
I : 
I ' 
I I I I 
bl 
i
l I \\ IT'O'N~IN-~--=~===============---------------.J&;LAroNW--·-~~ 
II~ ,/ ( 
I " I I I 
NI 
. 1 
°1 
i 
I 
i 
I : 
... _---_ .... _ .. ---_ .. ---
... ~ ........ -.~-.. ----
... -._ .. _- - --_ ... _--- . ---
~======= 
..... __ .. _. _ ... _- ----
I I I 
wli _. ___ , ___ .~ ___ ~ ____ .. _._. _____ ~ ___ .. __ J 
b 
Results: 
Chromatograms indicate that the pure Melatonin injection and the 
injection of the extracted sample are both melatonin - same retention 
times and same peak shapes. The second peak on the stripchart plot is 
propably vitamin 86 which is also found in the Schiff melatonin product. 
6 
</ 
;! 
~~ 
t 11 
1 G 
1 1 
t ") 
t 
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MELATONIN ANALYSIS 
Absorbance vs Concentration 
-----,~------------"" 
, 
k 
" 
i 
, 
(I 2 3 4 5 6 7 B 9 
Concentration (mg/100ml) 
o Calibration curve 
<> Extracted sample 
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